Diabetic Foot News and Research

RSS

IQWiG identifies additional recommendations for diabetes mellitus type 2 DMP

On 3 January 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with diabetes mellitus type 2.

4 Jan 2012

SANUWAVE Health third quarter revenues decrease 42% to $161,678

SANUWAVE Health, Inc. today reported financial results for the three and nine months ended September 30, 2011.

14 Nov 2011

APMA encourages 'Knock Your Socks Off' foot care campaign for people with diabetes

American Podiatric Medical Association Encourages Hispanic Health Awareness with "Knock Your Socks Off" Foot Care Campaign, Promotes Regular Foot Exams by Podiatrist to End Diabetes Complications

10 Nov 2011

Largest study on diabetes and foot ulcers

What's crucial for a diabetic's foot sore to heal is that the ulcer is superficial, blood circulation is normal, and the person has had diabetes for short time. This is shown in the world's largest diabetes study regarding foot ulcers, which has been carried out by the researcher Magdalena Annersten Gerhater at Malmö University in Sweden.

27 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011

SANUWAVE announces dermaPACE Phase III trial results on diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the Company's dermaPACE device will be the subject of a presentation at Plastic Surgery 2011, the American Society of Plastic Surgeons' National Meeting being held September 23-27 in Denver.

23 Sep 2011

Cardiff develops simple and effective wound test that could save NHS millions

Scientists in Cardiff are developing a simple but effective test to predict whether chronic wounds will respond to conventional treatment - which could save the NHS tens of millions of pounds annually.

20 Sep 2011

DJOFL second quarter net sales increase 14.5% to $277.8 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the second quarter of fiscal 2011, ended July 2, 2011.

16 Aug 2011

SANUWAVE second quarter revenues increase 40%

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

10 Aug 2011

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.

30 Jun 2011

Derma Sciences announces $29 million financing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has closed its previously announced private placement.

27 Jun 2011

Derma Sciences to raise $29M through private placement

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has entered into definitive agreements with select institutional investors to raise gross proceeds of approximately $29 million.

20 Jun 2011

LWW sponsors 26th Annual Clinical Symposium on Advances in Skin & Wound Care

The 26th Annual Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing will be held September 9-12, 2011, at the Gaylord National Hotel & Convention Center, National Harbor, MD.

7 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic foot ulcers, the percentage of patients treated with the therapeutic dose of DSC127 with complete healing at 24 weeks following trial enrollment was 73% in the intent-to-treat population and 85% in the per-protocol population, a difference of 27 and 33 percentage points, respectively, compared with patients treated with placebo/standard of care.

25 May 2011

Resection arthroplasty more effective for patients with diabetic foot ulcers

A recent study published in the March issue of Foot & Ankle International, the official scientific journal of the American Orthopaedic Foot & Ankle Society describes a possible amputation alternative for patients with neuropathic ulceration of the first metatarsophalangeal or big toe joint.

28 Apr 2011

CoDa Therapeutics raises $19.2 million in Series B financing

CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

18 Apr 2011

ULURU fourth quarter net loss decreases to $0.3 million

ULURU Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010.

1 Apr 2011

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2010.

30 Mar 2011